BACKGROUND AND PURPOSE: Combining statin and fibrate in clinical practice provides a greater reduction of triglycerides than either drug given alone, but the mechanism for this effect is poorly understood. Apolipoprotein AV (apoAV) has been implicated in triglyceride metabolism. This study was designed to investigate the effect of the combination of statin and fibrate on apoAV and the underlying mechanism(s). EXPERIMENTAL APPROACH: Hypertriglyceridaemia was induced in rats by giving them 10% fructose in drinking water for 2 weeks. They were then treated with atorvastatin, fenofibrate or the two agents combined for 4 weeks, and plasma triglyceride and apoAV measured. We also tested the effects of these two agents on triglycerides and apoAV in HepG2 cells in culture. Western blot and reverse transcription polymerase chain reaction was used to measure apoAV and peroxisome proliferator-activated receptor-alpha (PPARalpha) expression. KEY RESULTS: The combination of atorvastatin and fenofibrate resulted in a greater decrease in plasma triglycerides and a greater increase in plasma and hepatic apoAV than either agent given alone. Hepatic expression of the PPARalpha was also more extensively up-regulated in rats treated with the combination. A similar, greater increase in apoAV and a greater decrease in triglycerides were observed following treatment of HepG2 cells pre-exposed to fructose), with the combination. Adding an inhibitor of PPARalpha (MK886) abolished the effects of atorvastatin on HepG2 cells. CONCLUSIONS AND IMPLICATIONS: A combination of atorvastatin and fenofibrate increased apoAV and decreased triglycerides through up-regulation of PPARalpha.
BACKGROUND AND PURPOSE: Combining statin and fibrate in clinical practice provides a greater reduction of triglycerides than either drug given alone, but the mechanism for this effect is poorly understood. Apolipoprotein AV (apoAV) has been implicated in triglyceride metabolism. This study was designed to investigate the effect of the combination of statin and fibrate on apoAV and the underlying mechanism(s). EXPERIMENTAL APPROACH: Hypertriglyceridaemia was induced in rats by giving them 10% fructose in drinking water for 2 weeks. They were then treated with atorvastatin, fenofibrate or the two agents combined for 4 weeks, and plasma triglyceride and apoAV measured. We also tested the effects of these two agents on triglycerides and apoAV in HepG2 cells in culture. Western blot and reverse transcription polymerase chain reaction was used to measure apoAV and peroxisome proliferator-activated receptor-alpha (PPARalpha) expression. KEY RESULTS: The combination of atorvastatin and fenofibrate resulted in a greater decrease in plasma triglycerides and a greater increase in plasma and hepatic apoAV than either agent given alone. Hepatic expression of the PPARalpha was also more extensively up-regulated in rats treated with the combination. A similar, greater increase in apoAV and a greater decrease in triglycerides were observed following treatment of HepG2 cells pre-exposed to fructose), with the combination. Adding an inhibitor of PPARalpha (MK886) abolished the effects of atorvastatin on HepG2 cells. CONCLUSIONS AND IMPLICATIONS: A combination of atorvastatin and fenofibrate increased apoAV and decreased triglycerides through up-regulation of PPARalpha.
Authors: Len A Pennacchio; Michael Olivier; Jaroslav A Hubacek; Ronald M Krauss; Edward M Rubin; Jonathan C Cohen Journal: Hum Mol Genet Date: 2002-11-15 Impact factor: 6.150
Authors: L A Pennacchio; M Olivier; J A Hubacek; J C Cohen; D R Cox; J C Fruchart; R M Krauss; E M Rubin Journal: Science Date: 2001-10-05 Impact factor: 47.728
Authors: M H Criqui; G Heiss; R Cohn; L D Cowan; C M Suchindran; S Bangdiwala; S Kritchevsky; D R Jacobs; H K O'Grady; C E Davis Journal: N Engl J Med Date: 1993-04-29 Impact factor: 91.245
Authors: Michael Miller; Christopher P Cannon; Sabina A Murphy; Jie Qin; Kausik K Ray; Eugene Braunwald Journal: J Am Coll Cardiol Date: 2008-02-19 Impact factor: 24.094
Authors: Frank G Schaap; Patrick C N Rensen; Peter J Voshol; Carlos Vrins; Hendrik N van der Vliet; Robert A F M Chamuleau; Louis M Havekes; Albert K Groen; Ko Willems van Dijk Journal: J Biol Chem Date: 2004-04-16 Impact factor: 5.157
Authors: Ngoc Vu-Dac; Philippe Gervois; Heidi Jakel; Maxime Nowak; Eric Bauge; Helene Dehondt; Bart Staels; Len A Pennacchio; Edward M Rubin; Jamila Fruchart-Najib; Jean-Charles Fruchart Journal: J Biol Chem Date: 2003-03-12 Impact factor: 5.157
Authors: Núria Roglans; Elena Sanguino; Cristina Peris; Marta Alegret; Manuel Vázquez; Tomás Adzet; Cristina Díaz; Gonzalo Hernández; Juan C Laguna; Rosa M Sánchez Journal: J Pharmacol Exp Ther Date: 2002-07 Impact factor: 4.030
Authors: Huichao Chen; David B Clifford; Lijuan Deng; Kunling Wu; Anthony J Lee; Ronald J Bosch; Sharon A Riddler; Ronald J Ellis; Scott R Evans Journal: J Neurovirol Date: 2013-12-03 Impact factor: 2.643
Authors: Renée Deehan; Pia Maerz-Weiss; Natalie L Catlett; Guido Steiner; Ben Wong; Matthew B Wright; Gil Blander; Keith O Elliston; William Ladd; Maria Bobadilla; Jacques Mizrahi; Carolina Haefliger; Alan Edgar Journal: PLoS One Date: 2012-04-13 Impact factor: 3.240